170 related articles for article (PubMed ID: 32801166)
1. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
Nagy S; Kuhle J; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
[TBL] [Abstract][Full Text] [Related]
2. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
3. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
5. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.
Caliendo D; Grassia MC; Carotenuto A; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2024 Jan; 81():105135. PubMed ID: 38006850
[TBL] [Abstract][Full Text] [Related]
6. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Immunol; 2018; 9():2669. PubMed ID: 30524432
[TBL] [Abstract][Full Text] [Related]
7. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Takahashi K
J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Johnson TA; Shames I; Keezer M; Lapierre Y; Haegert DG; Bar-Or A; Antel J
Clin Immunol; 2010 Oct; 137(1):15-20. PubMed ID: 20599429
[TBL] [Abstract][Full Text] [Related]
9. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
10. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
[TBL] [Abstract][Full Text] [Related]
11. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Warnke C; Dehmel T; Ramanujam R; Holmen C; Nordin N; Wolfram K; Leussink VI; Hartung HP; Olsson T; Kieseier BC
Neurology; 2014 Dec; 83(23):2153-7. PubMed ID: 25361781
[TBL] [Abstract][Full Text] [Related]
12. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
[TBL] [Abstract][Full Text] [Related]
13. What happens after fingolimod discontinuation? A multicentre real-life experience.
Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J
J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943
[TBL] [Abstract][Full Text] [Related]
14. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
[TBL] [Abstract][Full Text] [Related]
17. Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.
De Masi R; Accoto S; Orlando S; De Blasi V; Pasca S; Scarpello R; Spagnolo L; Idolo A; De Donno A
BMC Neurol; 2015 Jul; 15():125. PubMed ID: 26227815
[TBL] [Abstract][Full Text] [Related]
18. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
[TBL] [Abstract][Full Text] [Related]
19. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
